Summary:
Psychiatric Care and Research Center is conducting a multi-center study to evaluate the efficacy of switching adult subjects with treatment resistant depression from a prior antidepressant treatment to intranasal esketamine plus a new antidepressant compared to switching to a new antidepressant plus intranasal placebo in improving depressive symptoms. This is a new antidepressant with a novel mechanism of action and will be given intranasally over a 4 week period.
Qualified Participants Must:
• Be between 18 and 64 years of age
•
Have failed to respond to between 1 and 5 different antidepressant medications in the current depressive episode
•
Not have Schizophrenia, Bipolar Disorder, or Substance Abuse within the past 6 months
Qualified Participants May Receive:
Compensation for time and travel may be possible.
Complete medical examination.